

Special Issue

Apoptosis—50 Years after Its Discovery

Message from the Guest Editors

Fifty years after its discovery (2022), we think that a Special Issue about the role of apoptosis in health and disease would be interesting, highlighting the balances/imbbalances between apoptosis and the cell cycle and other associated events for the maintenance of tissue homeostasis, namely, differentiation, migration, and programmed cell clearance. For this Special Issue authors are invited to review recent work or submit original studies in all areas of cell death research, with an emphasis on the aforementioned balances/imbbalances between apoptosis and other cellular processes and on novel physiological and pathological functions or regulatory mechanisms in normal tissues and in various diseases. Kerr JF, Wyllie AH, Currie AR 1972 Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics Br. J. Cancer 26 239–57.

Guest Editors

Prof. Dr. Cecilia M. P. Rodrigues

Research institute for Medicines (iMed.U.Lisboa), Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal

Dr. Fernando Capela e Silva

1. Department of Medical and Health Sciences, School of Health and Human Development, University of Évora, 7000-671 Évora, Portugal

2. Mediterranean Institute for Agriculture, Environment and Development (MED), University of Évora, 7000-671 Évora, Portugal

Deadline for manuscript submissions

closed (31 July 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/67858

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).